Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) – Stock analysts at Oppenheimer issued their Q1 2020 EPS estimates for shares of Aptose Biosciences in a report issued on Wednesday, March 13th. Oppenheimer analyst M. Biegler forecasts that the biotechnology company will earn ($0.23) per share for the quarter. Oppenheimer also issued estimates for Aptose Biosciences’ Q2 2020 earnings at ($0.60) EPS, Q3 2020 earnings at ($0.21) EPS and Q4 2020 earnings at ($0.21) EPS.

Several other analysts also recently weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and set a C$6.00 price target on shares of Aptose Biosciences in a research note on Friday, March 1st. HC Wainwright reiterated a “buy” rating and set a C$8.50 price target on shares of Aptose Biosciences in a research note on Monday, December 3rd. Finally, B. Riley reiterated a “buy” rating on shares of Aptose Biosciences in a research note on Friday, November 16th.

Aptose Biosciences stock opened at C$2.53 on Friday. The stock has a market cap of $86.89 million and a price-to-earnings ratio of -2.99. Aptose Biosciences has a fifty-two week low of C$2.08 and a fifty-two week high of C$5.97.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Article: What is the Gross Domestic Product (GDP)?

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.